• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center
 

Research Programs

Clinical-based Research

Lymphoma and Myeloma

Program Leadership

Jon Aster, MD, PhD

Lymphoma and Myeloma Program

The Lymphoma and Myeloma Program characterizes specific lymphoid malignancies at both the cellular and molecular levels, using state-of-the-art approaches such as murine models and broad-based transcriptional and genetic profiling. In addition to gaining basic insight into pathogenetic mechanisms and predisposing factors, these efforts help identify relevant rational treatment targets.

The Program has a long-standing interest in analysis and augmentation of host immune response to lymphomas and myelomas. Recently, investigators have developed an extensive outcomes database and have begun to analyze long-term toxicity and quality-of-life issues in lymphoma and myeloma patients.

The Lymphoma and Myeloma Program has four specific aims:

  • Determine the etiologies of specific lymphoid malignancies with emphasis on viral causes
  • Elucidate pathogenetic mechanisms underlying specific lymphoid neoplasms, focusing on:
    • Informative chromosomal translocations and murine models
    • Abnormalities of signal transduction pathways
    • Interactions between the tumor and its microenvironment
  • Develop novel therapeutic approaches to lymphoid malignancies, focusing on novel agents, risk-related therapy, high dose therapy with autologous or allogeneic stem cell support, tumor immunity including graft versus lymphoma effects, and tumor cell vaccines
  • Develop a comprehensive mechanism to analyze sociodemographic, clinical, treatment, and outcomes data on lymphoma patients.